Olatec Therapeutics
New York, US Β· 1 known investors
Olatec is a biopharmaceutical company developing oral NLRP3 antagonist therapeutics to treat acute and chronic inflammatory diseases including arthritis, heart failure, asthma, neurological conditions, and cancers. The company's lead compound, dapansutrile, targets the innate immune system to inhibit pro-inflammatory cytokines.
BiotechHealthtechMedical Devices
Investors Β· 1
Frequently asked questions
- What does Olatec Therapeutics do?
- Olatec is a biopharmaceutical company developing oral NLRP3 antagonist therapeutics to treat acute and chronic inflammatory diseases including arthritis, heart failure, asthma, neurological conditions, and cancers. The company's lead compound, dapansutrile, targets the innate immune system to inhibit pro-inflammatory cytokines.
- Who are Olatec Therapeutics's investors?
- Olatec Therapeutics's investors include Advection Growth Capital.
- Where is Olatec Therapeutics headquartered?
- Olatec Therapeutics is headquartered in New York, US.